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Foot-and-mouth disease virus (FMDV) is a picornavirus that causes an acute vesicular disease of cloven-hoofed animals. This virus
continues to be threat to livestock worldwide with outbreaks causing severe economic losses. However, very little is known about FMDV
pathogenesis, partially due to the inconveniences of working with cattle and swine, the main natural hosts of the virus. Here we demonstrate
that C57BL/6 and BALB/C adult mice are highly susceptible to FMDV infection when the virus is administered subcutaneously or
intraperitoneally. The first clinical signs are ruffled fur, apathy, humped posture, and wasting, which are followed by neurological signs such
as hind-limb paralysis. Within 2–3 days of disease onset, the animals die. Virus is found in all major organs, indicating a systemic infection.
Mice developed microvesicles near the basal layer of the epithelium, event that precedes the vesiculation characteristics of FMD. In addition,
a lymphoid depletion in spleen and thymus and severe lymphopenia is observed in the infected mice. When these mice were immunized with
conventional inactivated FMDV vaccine, they were protected (100% of vaccinated animals) against challenge with a lethal dose of FMDV.
The data indicate that this mouse model may facilitate the study of FMDV pathogenesis, and the development of new effective vaccines for
FMD.
D 2004 Elsevier Inc. All rights reserved.
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Foot-and-mouth disease virus (FMDV) is a member of
the family Picornaviridae, genus Aphthovirus, that causes a
highly contagious and economically devastating disease of
cloven-hoofed livestock, characterized by the appearance of
vesicles on the feet and mouth (Bachrach, 1978; Rowlands,
2003; Sobrino and Domingo, 2004). The economic and
social impact of foot-and-mouth disease (FMD) can be
catastrophic when an outbreak occurs in FMD-free countries0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.11.005
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E-mail address: nsevilla@cbm.uam.es (N. Sevilla).populated with immunologically naive animals. This is the
case of the FMD outbreaks in Taiwan in 1997 and in United
Kingdom in 2001 resulted in the culling of millions of
infected and in-contact, susceptible animals, and billions of
Euros in direct and indirect costs (Gibbens et al., 2001;
Knowles et al., 2001; Yang et al., 1999).
Similar to other RNA viruses, FMDV viral populations
follow a quasispecies dynamics as a result of the high
mutation rates during genome replication (reviewed in
(Domingo et al., 2001). This genetic heterogeneity and
diversification is reflected in its serological diversity, with
seven antigenically distinct serotypes, O, A, C, South
African Territories (SAT) 1, SAT 2, SAT3, and Asia 1
(Pereira, 1981). Immunity to one serotype does not provide
protection against the others complicating the design of
vaccines. In addition, many subtypes within one serotype,05) 384–396
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have been identified. This level of heterogeneity is also
reflected in the severity of resulting disease in natural hosts
that varies with the virus strain (reviewed in (Donaldson,
2004). By comparing reactivity with monoclonal antibodies,
it has been shown that FMDV populations are composed of
a continuum of antigen variants, with amino acid sub-
stitutions affecting several antigen sites on the viral particle
(Mateu, 1995). The design of effective vaccines is made
more difficult by this antigenic heterogeneity since vaccines
must match the antigenic properties of the circulating
viruses.
The mechanisms underlying the pathogenesis and the
determinants of protective immunity to FMDV are not well
understood. A basic understanding of FMDV pathogenesis
and the type of immune response needed to confer full
protection are needed. Studies involving the natural hosts
of FMDV are limited by the complexity of the system and
the lack of reagents to define components of the immune
response. Even use of guinea pigs meets with considerable
limitations regarding host genetics and reagents to charac-
terize immune responses (Balamurugan et al., 2003; Bittle
et al., 1982; Dunn et al., 1998; Huang et al., 1999;
Knudsen et al., 1979; Nunez et al., 2001). To circumvent
some of these problems, an adequate system would be the
use of adult mice because of the knowledge of its genetics
and its manageability. Mice have been used as an
alternative to the natural host to study many viral diseases
such as those associated with infection by Ebola virus
(Bray et al., 1998), Hantaviruses (Wichmann et al., 2002),
Dengue virus (Huang et al., 2000), Venezuelan equine
encephalitis virus (Gleiser et al., 1961; Jackson et al.,
1991), and Herpes simplex virus (Hayashi et al., 1986),
among others. The use of murine models for these diseases
has helped elucidating several mechanisms of the patho-
genesis of these viruses, which are difficult to achieve
using the natural hosts.
Skinner (1951) demonstrated that unweaned mice could
be readily infected intraperitoneally with most serotypes
of FMDV. Since then, unweaned mice have been used
extensively in many laboratories for the detection and
titration of virus and for serum neutralization tests
(Heatley et al., 1960; Skinner et al., 1952; Subak-Sharpe,
1961). FMDV induces a rapidly fatal infection in these
mice characterized by muscular paralysis of the limbs,
showing severe macroscopic degenerative changes in the
limb muscles, in other skeletal muscles, and in the
myocardium (Platt, 1956). However, this susceptibility
wanes rapidly with increasing age, so that mice aged
between 3 and 4 weeks rarely become critically ill. There
appears to be in agreement with the literature that normal
adult mice do not show disease symptoms even when
inoculated with very large doses of FMDV (Borca et al.,
1986; Lopez et al., 1990; Piatti et al., 1991; Subak-
Sharpe, 1961). A subclinical infection was produced in
some strains (CH3, Swiss, BALB/c and nude) of adultmice inoculated with FMDV serotype O or A (Collen et
al., 1984, 1989; Fernandez et al., 1986). Viraemia lasted
for 48 to 72 h post-inoculation and production of
neutralizing antibodies coincided with virus clearance
(Borca et al., 1986; Collen et al., 1984; Lopez et al.,
1990). This murine model system has been used to study
some aspects of the immune response to FMDV (Perez
Filgueira et al., 1995; Piatti et al., 1991; Wigdorovitz et
al., 1997). However, it is less suitable for the study of the
role of the immune system and host genetic factors
involved in the pathogenesis of FMDV due to the lack of
symptoms associated with the infection. Here, we report
that several serotypes and viral variants of FMDV are
lethal for the adult inbred mouse strains, C57BL/6 and
BALB/C. The virus spread in almost all organs tested,
causing a systemic infection. In addition, the animals
show a severe lymphopenia as well as microscopic lesions
in several organs similar to those described in the natural
hosts. Furthermore, mice vaccinated with a classical
FMDV inactivated vaccine show complete protection
against a lethal dose of FMDV.Results
FMDV serotype C causes a lethal infection in adult
laboratory mice
It has been previously described that a viraemia could
regularly occur in adult mice after intraperitoneal inocu-
lation with different strains of FMDV, although mice did
not shown clinical symptoms or die (Fernandez et al.,
1986). In an attempt to develop an adult mouse model for
FMDV in which mice show disease symptoms, we tested
the susceptibility of different laboratory mouse strains to
FMDV C-S8c1. Adult C57BL/6, BALB/C, SJL/J and
Swiss mice (8 weeks old) were infected in the left rear
footpad (LRFP) with 105 PFUs of FMDV C-S8c1. Since an
antiviral protective response is highly dependant on the
migration of different components of the immune response
to the site of inoculation, we chose footpad sc inoculation
to facilitate virus spread without early intervention of the
immune system that could lead to virus elimination. Under
these conditions, mouse strains showed different suscept-
ibility to FMDV (Fig. 1). SJL/J mice did not show any
symptoms or death following viral infection. Swiss, BALB/
C and C57BL/6 mice were susceptible to infection and
showed a similar disease course at different times post-
inoculation. Disease was characterized by apathy, ruffled
fur, humped posture, and mild wasting at 24 h post-
inoculation. At late stages of the disease, the animals
developed neurological signs such as ataxia in the
hindlimb. The quick progression of the disease led to
death of most animals within 48 to 72 h post-inoculation
(Fig. 1). LD50 values were 50 PFU for C57BL/6, 10
4 PFU
for BALB/c and 106 PFU for Swiss mice; SJL/J mice did
Fig. 1. Susceptibility of adult mice to FMDV infection. Different strains of
laboratory mice (8 weeks old, 6 mice per group) were subcutaneously
inoculated in the footpad with 105 PFUs of FMDV C-S8c1. The mice were
observed every 4 h for the first 48 h and every 24 h for 7 days. Except for
SJL/J, all other animals were susceptible to infection. C57BL/6 and BALB/c
showed similar disease course. Procedures are detailed in Materials and
methods.
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infection (Fig. 2). Since C57BL/6 mice showed the highest
susceptibility to FMDV, this mouse strain was used for
further experiments. In order to evaluate the influence of
the route of inoculation in the outcome of the disease, the
virulence of FMDV C-S8c1 in C57BL/6 mice was alsoFig. 2. Survival curves of C57BL/6, BALB/c, SJL/J, and Swiss mice infected with
injected in the footpad with 10-fold dilutions of FMDV C-S8c1; the number of P
indicate that the survival curves are superimposable. LD50 values re given in thedetermined after ip inoculation. The progression of the
disease led to death of most animals within 48 to 72 h
However, C-S8c1 was more virulent after ip inoculation,
showing a LD50 of 10 PFU. Since the natural route of
infection in the natural host is by exposition to aerosols, we
carried out additional experiments in which mice were
infected by the oronasal route. These mice, after infection
with the highest amount of virus used (106 PFUs), did not
show any symptom or death associated with viral infection.
This indicates an influence of the inoculation route in the
outcome of the disease.
Replication and spread of FMDV C-S8c1 in the mouse
To determine the dissemination of the virus beyond the
footpad to serum and other tissues, time course studies were
performed and the virus titer in serum and various tissues
(draining lymph node (popliteal) [PLN], spleen, thymus,
pancreas, liver, lung, heart, and brain) was determined at
different times post-inoculation with 104 PFU of C-S8c1 in
the LRFP (Fig. 3). Viral titers in serum peaked between 24
and 36 h post-inoculation (hpi) at 106 to 107 PFU/ml
(Fig. 3A). The first tissue to be reached by the virus was the
liver (Fig. 3B), where virus was detected as early as 4 hpi
(102 PFU/g), with viral titers increasing thereafter until
death (reaching titers of 104 PFU/g). By 8 hpi, virus was
detected in spleen, pancreas, heart and thymus, reachingFMDV C-S8c1. Mice (8 weeks old, 6 mice per group) were subcutaneously
FUs inoculated is indicated on each survival curve. Values shown together
text, and procedures are detailed in Materials and methods.
Fig. 3. FMDV C-S8c1 titers in serum and several organs of C57BL/6 mice. Mice (8 weeks old) were inoculated in the LRFP with 104 PFUs of FMDV C-S8c1.
(A) Viral titers in serum were determined as described in Materials and methods. Each point represents the average of the viral titer of four animals. The
detection limit was approximately 10 PFUs. Data are given by PFU/ml F SD. (B) At the indicated times post-inoculation, four mice per group were sacrificed
and heart, lung, brain, kidney, liver, pancreas, spleen, thymus, and draining lymph node (PLN) were harvested for viral titer determinations. The detection limit
was approximately 10 PFUs. Standard deviations are given. Procedures are detailed in Materials and methods.
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36 hpi (103 PFU/g). Viral infectivity was below the limit of
detection (10 PFU/g) in the lung and brain until 24 hpi (103
and 102 PFU/g, respectively), suggesting a slower virus
spread to these tissues (Fig. 3B). Virus was detected in all
the organs tested, indicating a systemic infection. In
general, virus failed to clear from any of the organs
analyzed, and remained at or near peak titers until the
death of the animals. The only exception was the PLN in
which virus replication was detected at 24 hpi (100 PFU/g)
with a drop in titer below the limit of detection by 48 hpi
(Fig. 3B). These results suggest that the virus does not
spread to the PLN, and that replication may be taking placemainly at or near the inoculation site, and then spreading
throughout the body.
Susceptibility of C57BL/6 mice to other FMDV serotypes
and variants
To determine whether C57BL/6 mice were susceptible
to FMDV of different serotypes, C57BL/6 mice were
inoculated in the LRFP with tenfold serial dilutions of
FMDV A22 and SAT-1. Mice infected with SAT-1
showed similar symptoms to those shown after infection
with FMDV C-S8c1, with an LD50 of 10 PFU, similar to
the LD50 for C-S8c1 (Fig. 4A). However, mice inoculated
Fig. 4. Virulence of different FMDV serotypes and viral variants for C57BL/6 mice. Mice (8 weeks old, 6 per group) were subcutaneously inoculated in the
footpad with 10-fold serial dilutions of each virus. (A) Survival curves of mice infected with FMDV SAT1 or A22. (B) Survival curves of mice infected with C-
S8c1p100 or C-S8c1 MARLS. The number of PFUs administered to the mice is indicated on each survival curve. Values shown together indicate that the
survival curves are superimposable. LD50 values are given in the text, and procedures are detailed in Materials and methods.
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(Fig. 4A). With the highest dose used to infect C57BL/6
mice (105 PFUs), only 33% of the mice died displaying
similar symptoms to those observed after infection with
FMDV C-S8c1 or SAT-1, within 24–48 h after infection.
Thus, C57BL/6 mice showed different susceptibility to
three FMDV serotypes, C, A, and SAT-1.
Additionally, we carried out experiments to determine the
susceptibility of C57BL/6 to two variants of C-S8c1
generated by serial passage of C-S8c1 in BHK-21 cells
(Charpentier et al., 1996; Martinez et al., 1997). We chose C-
S8c1p100, the population that resulted after 100 passages of
C-S8c1 in BHK-21 cells, that shows higher virulence for
BHK-21 cells than C-S8c1 (Martinez et al., 1997). The
second variant tested was MARLS, a clonal population
selected from C-S8c1 passaged 200 times in BHK-21 cells,
for its resistance to monoclonal antibody (Charpentier et al.,
1996). C-S8c1 p100 showed an LD50 of 10
5 PFUs,
approximately 103 times higher than the parental virus
FMDV C-S8c1, while MARLS did not cause any death of
C57BL/6 even at the highest dose used (106 PFUs) (LD50 N
106 PFUs) (Fig. 4B). These data suggest that C57BL/6 mice
are adequate to detect differences in virulence among FMDV
variants, and that multiple passages of FMDV C-S8c1 in
BHK-21 cells resulted in an increase in replication for BHK-
21 cells and a decrease of virulence for C57BL/6 mice.FMDV infection of adult mice causes microscopic lesions
that are characteristic of FMD
In order to better describe and understand the causes of
lethal disease by FMDV in adult mice, histological analyses
were performed on material of several organs taken from
infected and uninfected C57BL/6 mice. Gross findings
consisted on mild to severe edema of body cavities, mostly
hydrothorax and hydropericardium, subcutaneous edema in
the cervical area, enlarged heart, and reddish lungs.
Histological examination of the heart showed signs of
dilatation and mostly the right ventricle and the lung showed
hyperemia, with a mild increase in the septum sizes (Fig. 5,
panels A and B). A mild to severe lymphoid depletion was
observed in the thymus, with an increase in the presence of
btangible-bodyQ macrophages, showing the typical bstarry-
skyQ appearance (Figs. 5A, B). Interestingly, the spleen and
popliteal lymph nodes did not show significant changes.
The footpad showed an increase in the degeneration of the
cells of the stratum spinosum, mostly near the basal layer,
showing intracellular edema and pyknotic nuclei. Moreover,
intercellular edema was also found mostly in the stratum
spinosum, and occasionally, microvesicles were found near
the basal layer (Fig. 6). The types of lesions are typical of
vesicular diseases, and are seen in FMDV infection of
several natural hosts (see Discussion). The results suggest
Fig. 5. Tissue sections of lung and thymus from FMDV-infected adult C57BL/6 mice. Mice were infected with 104 PFUs of FMDV subcutaneously in the
LRFP. Tissues were harvested at 48 hpi. Hematoxylin and eosin staining are shown. Panel A, (A) Thymus from inoculated animal. Hyperemia and lymphoid
depletion, mostly in the cortex, with the presence of numerous btangible-bodyQ macrophages that confers the typical bstarry-skyQ appearance, 100. (B)
Thymus from a non-inoculated, control animal, 100. (C) Lung from an inoculated animal. Hyperemia and increased size of interalveolar septa, 100. (D)
Lung from a non-inoculated (naRve) control animal, 100. Panel B. Higher magnification (200) of additional tissue sections in which the increased size of the
interalveolar septa in FMDV infected lungs is shown. Procedures are detailed in Materials and methods.
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typical of vesicular diseases that did not evolve to produce
gross, macroscopic vesiculation.
In those infections that did not lead to death (oronasal
infection) the histological examination of the lungs showed
a marked increased in the septum sizes and hyperemia (data
not shown). Examination of spleen showed a decreased in
white pulp compared to uninfected control mice and, as a
consequence, lost of marginal zone (data not shown). These
findings indicate that following oronasal FMDV infection,
C57BL/6 mice develop microlesions similar to those
described in natural hosts (see Discussion).
Profound lymphopenia and lymphoid depletion during acute
infection of mice with FMDV
Lymphocytes and white blood cells (WBC) were
monitored in FMDV-infected C57BL/6 mice. Mice were
inoculated with 104 PFUs of FMDV C-S8c1 or PBS in the
LFRP. As compared to the mock-infected mice (PBS), at 24hpi the FMDV infected mice had a significantly (P b 0.001)
decreased lymphocytes and WBC count (Fig. 7A). The
proportion of monocytes (M), polymorphonuclear leuko-
cytes (PMN) and lymphocytes in blood of FMDV-infected
mice were significantly altered when compared with control
animals (Fig. 7A). The observed decrease in the percentage
of lymphocytes and corresponding increase in the percent-
age of PMN suggest that the loss of WBC could be
attributed to loss of lymphocytes relative to control animals.
The rapid removal of lymphocytes could be due either to
cells being sequestered from the circulation and migration to
lymphoid tissue, or to virus-induced apoptosis. To deter-
mine whether lymphocyte depletion occurred also in
lymphoid tissue, spleen lymphocytes were analyzed by
flow cytometry. C57BL/6 mice were inoculated in the LRFP
with 104 PFU of FMDV C-S8c1. At 24 hpi, spleens from
FMDV-infected and mock-infected mice were harvested,
showing a profound increase in the spleen size as compared
to the mock-infected mice. Counting of cells showed a 4-
fold increase in the number of splenocytes (Fig. 7B). Double
Fig. 6. Tissues sections of footpad from C57BL/6 mice inoculated with
FMDV. Mice were infected with 104 PFUs of FMDV subcutaneously in the
LRFP. Tissues were harvested at 48 h post-inoculation. Hematoxylin and
eosin staining are shown. (A) Inoculated animal. Intracellular spongiosis,
vacuolization and pyknosis of cells from the spinous layer (arrows), 630.
(B) Inoculated animal. Intercellular oedema in the spinous layer and
formation of a suprabasilar vesicle (arrow), 400. (C) Same tissue of a non-
inoculated, control animal, 400. Procedures are detailed in Materials and
methods.
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significant loss of CD4+ and CD8+ T cells in spleen of
FMDV infected mice (Fig. 7B). The induction of this loss of
T cells applied to both T cell subsets equally, with no
statistically significant difference between CD4+ and CD8+
T cell loss in infected mice. These data indicate that
lymphocyte depletion also occurred in lymphoid organs,
suggesting that the lymphocytes may be dying as a result of
the viral infection.
To identify if lymphocytes were infected by FMDV,
peripheral blood lymphocytes (PBLs) were purified from
peripheral blood from FMDV C-S8c1-infected and naive
mice. Cells were labeled with specific monoclonal anti-
bodies to CD8, CD4, and B220 surface markers couple to a
fluorochrome probe. This was complemented with the use
of an antibody to FMDV 3D or FMDV VP1 to differentiate
between viral replication and bound virus, coupled to adifferent and distinct fluorochrome, thereby allowing
detection of viral antigen in the specifically marked cell
type. FMDV C-S8c1 primarily infected CD8+ and B220+
cells with only minimal to negligible infection of CD4+ T
cells (Fig. 7C). These data indicate that CD8+ T cells and
B220+ lymphocytes were infected by FMDV, possibly
contributing to the T cell lymphocyte depletion observed.
However, the fact that CD4+ T cells were not infected
suggests that other mechanism that direct viral infection
could be implicated in the lymphocyte depletion in FMDV-
infected mice.
Immunized mice are completely protected against a lethal
FMDV challenge
The clinical course, distribution of virus in the body, and
pathological findings indicated that FMDV caused a
systemic lethal infection in adult, immunocompetent
C57BL/6 mice. To provide further proof that FMDV was
the causative agent of the disease in these animals and that
mice could respond to FMDV vaccine antigen, we
performed vaccination protection experiments. Adult
C57BL/6 mice were immunized with chemically inactivated
FMDV C-S8c1 vaccine (Bahnemann, 1975). The vaccine
was administered by two consecutive intraperitoneal injec-
tions of the equivalent to 106 PFU at intervals of 2 weeks.
Following each injection, antibody titers were determined
by ELISA. All immunized animals, but not control animals
inoculated with PBS, developed an antibody response,
indicating successful immunization (Fig. 8A). Subsequently,
2 weeks after the last immunization, immunized and control
animals were challenged in the left rear footpad with 104
PFUs of FMDV C-S8c1. While all control animals died,
100% of the immunized animals were protected against a
lethal challenge (Fig. 8B). This result indicates that
protective immunity was achieved and supports the notion
that FMDV was the causative agent of disease and death of
adult C57BL/6 mice.Discussion
This new mouse model for the study of FMDV
infections has unique features that open the possibility to
study in the same host-virus system susceptibility and
resistance to lethal infection, immunobiology of infection
and vaccine efficacy, in ways that are not approachable with
the natural hosts, or other animal model systems for FMDV.
Unlike other animal systems, the advantage of the mouse
model is not only the availability of a wide variety of
reagents, but also the use of an inbred mouse strain with a
uniform genetic background. Furthermore, the potential of
using genetically altered mice to study many aspects of the
immune response to the virus opens new fields of research
in the analysis of the immune response to FMDV infection
in vivo.
Fig. 7. Lymphopenia and T cell depletion in FMDV infected C57BL/6 mice. Mice were inoculated in the LRFP with 104 PFU of FMDV C-S8c1 and sacrificed
at 24 hpi. (A) Blood was collected and the WBC and lymphocytes counts were determined as described in Materials and methods. Leukocytes are indicated as
follow: mononuclear cells (M), polymorphonuclear cells (PMN) and lymphocytes (L). Values were compared to control samples obtained from mock-infected
mice. Data are shown as the average of resultsFSD, with n = 8 for the infected and n = 5 for the mock-infected mice. Asterisks denote a statistically significant
reduction in infected when compared to mock-infected mice (Student’s t test, P b 0.05). (B) Spleens were harvested from FMDV-infected or mock-infected
mice at 24 hpi and the total splenocyte number was determined. Flow cytometric analyses were performed using antibodies directed against CD4 and CD8a to
determine the number of splenic T cells. A minimum of 50,000 events was gated, and data were plotted as the percentage of positive events FSD for each
population of T cells. Asterisks denote a statistically significant reduction in infected when compared to mock-infected mice (Student’s t test, P b 0.05). (C)
Comparative levels of infectivity in T cells caused by FMDV C-S8c1. In each experiment, four adult C57BL/6 mice were injected in the LRFP with 104 PFU of
virus, and were sacrificed at 12 (white bars) and 24 (black bars) hpi (see Materials and methods). PBLs were isolated from total blood and were labeled with
cell-specific monoclonal antibodies to CD4, CD8, and B220. Subsequent intracellular staining using specific antibody to FMDV VP1 (antibody 2E5) or 3D
(antibody 3H11) was performed, followed by FACS. The graph represents percentages of cells in each subset infected with FMDV C-S8c1.
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number of variables, including dose, route of inoculation
and genetic background of the mouse, and the virus. SJL/J
and Swiss mice were less susceptible to FMDV C-S8c1
than C57BL/6 and BALB/c mice, suggesting that mouse
susceptibility to FMDV may be linked to genetic factors. Ithas been amply documented that the route of inoculation is
another important determinant of the outcome of viral
infections (Bray et al., 1998; Houtman and Fleming, 1996;
Rai et al., 1996; Turner and Moyer, 2002; Wichmann et al.,
2002). Subcutaneous (footpad) and ip inoculations of
C57BL/6 mice with FMDV were lethal, although ip
Fig. 8. Protection of vaccinated C57BL/6 mice against a lethal FMDV
challenge. Mice (8 weeks old, 18 per group) were immunized twice by
intraperitoneal administration of an inactivated virus vaccine, prepared as
described in Materials and methods. (A) Sera from mice previous to
immunization (pre-immune), day of the second booster (2nd boost), day of
viral challenge (104 PFUs of FMDV C-S8c1 in the LFRP) and 48 hpi were
used to determine antibody (Ab) titers against FMDV by ELISA, as
described in Materials and methods. In contrast to the controls animals (not
shown), all immunized mice developed an antibody response, indicating
successful immunization. (B) While all control animals died, protective
immunity was achieved in 100% of the immunized mice.
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since sc inoculation generally produces a slower replication
and dissemination of the virus, which may allow sufficient
time for the host to activate clearance mechanisms. An
important difference between the sc and ip routes of
infection that may explain differences in outcome is the
antigen-presenting cell populations involved in initiating the
immune response. Sc infections involve peripheral dendritic
cells (DC) populations, such as Langerhans cells or
lymphoid interdigitating DC as the initial presenting cells,
whereas ip infection probably results in presentation to T
cells via peritoneal macrophages and macrophage-derived
DC. Differences in viral kinetics between the two routes of
infection may, therefore, be due to differences in the
antigen-presenting cell populations or to the cytokine milieu
associated with peripheral DC and peritoneal macrophages
(Banchereau et al., 2000; Pulendran et al., 2001). Oronasal
inoculation, however, did not lead to death in C57BL/6mice although the mice developed microscopic lesions. The
resistance shown by C57BL/6 mice to FMDV when
inoculated by the oronasal route compares to the relative
resistance that swine show to infection with airborne
FMDV suggested that a dose of more than 800 TCID50
is required to cause infection and typical disease (Alex-
andersen and Donaldson, 2002). For all that, it could be
possible that the virus spread slower after oronasal
inoculation and the immune system control the infection
before the virus causes a systemic infection. Experiments
are currently being done to understand the different outcome
of FMDV infection in mice depending of the inoculation
route.
The classical description of viral pathogenesis holds that
viruses first replicate at the site of inoculation, followed by
spread to the draining lymph node (Mims et al., 1995;
Nathanson, 1980). The presence of FMDV in the draining
lymph node (PLN) was documented at 24 hpi, after viremia
had been established (Fig. 3), suggesting that FMDV may
not require to infect DCs to move to the draining lymph
node. In other viral infections, the detection of early virus in
the draining lymph nodes has been associated with infection
of Langerhans cells in the footpad followed by migration of
these cells to the draining lymph node (Hertel et al., 2003;
MacDonald and Johnston, 2000).
Histological analysis of FMDV-infected mice at 48 hpi
shows a similarity between lesions found in the footpad
and those described during infection of the natural hosts
(reviewed in (Meyer and Knudsen, 2001). The stratum
spinosum shows a degeneration of the body cells that
corresponds with pyknotic nuclei. The appearance of
microvesicles near the basal layer suggests that FMDV
induces the formation of vesicles in the footpad, a main
characteristic of the disease in the natural host. These
observations imply that although the development of
epidermal vesicles in C57BL/6 mice infected with FMDV
was not apparent in a macroscopic analysis, the events
preceding vesiculation were observed. The lesions which
FMDV produces in adult C57BL/6 mice are quite differ-
ent, in many respects, from those described for infection
of young mice (Platt, 1956). In 7-day-old mice, FMDV
has a marked myopathic affinity, and produces extensive
destruction of striated muscles, while in the mature
animal, it elicits the more typical epithelial reaction.
Similarly, in cattle the virus may produce rapid death in
calves by a necrotizing effect on striated muscle tissue,
while in the fully grown animal the lesions are predom-
inantly epithelial.
A profound lymphopenia has been described during the
acute infection of swine with FMDV (Bautista et al., 2003).
In our mouse model system, we have shown that there is a
significant lymphopenia and lymphoid depletion in lym-
phoid organs at 24 hpi that affects all T cell subsets,
creating a transient immunosuppression. The analysis of
viral replication in lymphocyte subsets shows that FMDV
replicates in CD8+ and B220+ cells. As the percentage of
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induction of apoptosis in lymphocytes by bystander effect.
In fact, the lack of FMDV infection in CD4+ cells strongly
suggests that other factors different to direct viral infection
are playing a role in cell death. One possibility could be
activated monocytes expressing several soluble mediators
of apoptosis, including tumor necrosis factor alpha (TNF-),
CD30L, FasL, 4-1BBL, and TNF-related apoptosis-induc-
ing ligand (TRAIL) (Ashkenazi et al., 1999; Dockrell et al.,
1998; Pauza et al., 2000; Yang et al., 2003). Any of these
factors could induce cell death in lymphocyte populations
in FMDV-infected mice. The role of some of these
molecules in the induction of lymphocyte death is the
focus of current investigations in our laboratory. Addition-
ally, the effect of secreted soluble factors by monocytes/
dendritic cells probably plays a significant role in the ability
of the virus to spread systemically in the mouse and to
cause death. The significance and contribution of the
lesions described to death is difficult to assess since we
have not found any highly destructive effect upon any
particular tissue analyzed. A cytokine-mediated lethality
during viral infection cannot be excluded (Kapcala et al.,
1995).
The differences observed among FMDV serotypes in
disease course after inoculation of C57BL/6 mice (Fig. 4A)
are striking. Differences in pathogenicity associated to
serotypes have been described for other viral infections
(Tyler and Fields, 1990), but it is not well known for FMDV.
In addition, two viruses, C-S8c1p100 and C-S8c1MARLS,
which are closely related both evolutionarily and antigeni-
cally(Charpentier et al., 1996) differ in their pathogenic
properties for C57BL/6 mice. This may allow the mapping
of virulence determinants and may help defining compo-
nents of a protective response against FMDV.
The protection mediated by inactivated whole FMDV
vaccine in C57BL/6 mice infected with a lethal dose of
FMDV C-S8c1 was complete, in that 100% of the animals
did not show any symptom or death associated with the
infection. This result strongly supports the involvement of
FMDV in the pathological processes described in this work
and, moreover, suggests that the mouse may be an adequate
model system to compare vaccine candidates. However, it
remains to be seen whether with other vaccine formulations,
the capacity to protect mice parallels the capacity to protect
natural hosts.
In conclusion, we have developed an adult mouse model
to study FMDV infections. The virus causes a lethal
systemic infection in several inbred strains of adult,
immunocompetent laboratory mice. This is the first time
that death of adult mice is associated with FMDV infection.
Even though mice are not known to be natural hosts for
FMDV, by virtue of the detailed knowledge of their genetics
and immunological mechanisms, this host will provide data
that may contribute to guide in experiments for the
understanding of the mechanisms of FMDV infection in
natural hosts.Materials and methods
Animals
C57BL/6, BALB/C, SJL/J and Swiss mice were pur-
chased from Harlan Interfauna Iberica, S.L. All mice used
were matched for sex and age (females, 8–10 weeks). Mice
were maintained under pathogen-free conditions and
allowed to acclimatize to the biosafety level 3 (BSL3)
animal facility at the Centro de Investigacio´n en Sanidad
Animal, INIA, Madrid, for 1 week before use in our
experiments. All experiments with live animals were
performed under the guidelines of the European Community
(86/609) and were approved by the site ethical review
committee.
Viruses and cells
Viruses were growth in baby hamster kidney cells
(BHK) as described (Domingo et al., 1980). Procedures
for infection of BHK-21 cell monolayers with FMDV in
liquid medium and for plaque assays in semisolid agar
medium have been described previously (Baranowski et al.,
1998; Domingo et al., 1980; Sobrino et al., 1983). The
FMDV C-S8c1 is a plaque-purified derivative of natural
isolate C1-Sta Pau-Spain 70, a representative of the
European subtype C1 FMDVs (Sobrino et al., 1983).
FMDV C-S8c1p100 is the virus C-S8c1 propagated 100
times in cell culture (Martinez et al., 1997). FMDV
MARLS is a monoclonal antibody escape mutant obtained
from FMDV C-S8c1p213 (C-S8c1 passaged 213 times in
BHK-21 cells) (Baranowski et al., 1998; Charpentier et al.,
1996). FMDV A22 and SAT1 were kindly provided by E.
Blanco, Centro de Investigacio´n en Sanidad Animal, INIA,
Madrid.
Animal infection and preparation of samples
Mice were infected with FMDV either subcutaneously
(sc) in the left rear footpad (LRFP) (50 Al) or intra-
peritoneally (ip) (100 Al) with different amount of viruses.
The oronasal inoculation was done in a volume of 50 Al.
Mice were examined for clinical symptoms twice daily.
LD50 were calculated by the method of Reed and Muench
(1938), after inoculation of mice with 10-fold serial
dilutions of virus. At varying times post-infection, several
mice were euthanized and organs (liver, lung, spleen,
heart, kidney, pancreas, brain, popliteal lymph node
[PLN], and thymus) were harvested and weighed. Half
of the tissues were used for histological analyses. The
other half was homogenized using an Omni tissue
homogenizer (Omni International). Serum was isolated
from whole blood that was obtained from the intraorbital
sinus. The amount of infectious virus was measured by
plaque assay on BHK cells as described (Domingo et al.,
1980).
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Blood was collected from the intraorbital sinus in 5 AM
EDTA at different times post-inoculation. The anticoagu-
lated blood sample was thoroughly mixed and analyzed on
an AcT Hematology analyzer (Beckman Coulter, Hialeah,
FL) following manufacturer’s directions. The percentages of
leukocyte populations (monocytes, polymorphonuclear leu-
kocytes and lymphocytes) were determined by staining with
May–Grunwald–Giemse and counting at least 300 cells per
sample.
Histopathology
Samples from different tissues and organs were taken and
fixed in 10% buffered formalin (pH 7.2) for histopatho-
logical studies. After fixation, samples were dehydrated
through a graded series of alcohol to xylol and embedded in
paraffin wax. Sections of 4-ı`m-thick were cut and stained
with hematoxylin and eosin (H&E) for histopathological
analysis.
Isolation of spleen cells, peripheral blood lymphocytes
(PBL) and flow cytometric analysis
Spleens were obtained from C57BL/6 mice infected
with FMDV C-S8c1. Single cells were then obtained by
mechanical disruption. Cells were pelleted by centrifuga-
tion and resuspended in staining buffer (PBS containing
2% (vol/vol) fetal bovine serum and 0.2% (wt/vol) NaN3)
for flow cytometry. PBLs were isolated from peripheral
blood of C57BL/6 mice infected with FMDV C-S8c1.
Briefly, fresh heparinized peripheral blood was mixed with
an equal volume of phosphate-buffered saline (PBS).
Ficoll-Hypaque (density 1.007 g/litter) was layered under-
neath the blood/PBS mixture and centrifuged 30 min at
900  g. The mononuclear cell layer was transferred to
another tube, washed, and counted with Trypan Blue to
determine viability. To analyze the expression of cell
surface molecules, we used monospecific antibodies,
fluorochrome dyes, and flow cytometry, as described
(Sevilla et al., 2000). The antibodies used were rat anti-
mouse CD8a-PerCp, rat anti-mouse CD4-FITC and anti-rat
B220-PE (all from BD Pharmingen, San Jose, CA, USA).
After staining, cells were fixed in PBS/1% fetal bovine
serum/4% PFA (wt/vol). Affinity-purified antibody to
FMDV-3D (3H11) was conjugated to Alexa-488 according
to the protocol recommended by the manufacturer (Molec-
ular Probes) and used for intracellular detection of FMDV
3D. Ascites of the antibody FMDV-VP1 (2E5) was used to
detect FMDV VP1. An anti-mouse conjugated to Alexa-
488 was used as secondary antibody for FMDV-VP1. Cells
were acquired using a FACSCalibur flow cytometer
(Becton Dickinson, Franklin Lakes, NJ, USA). Dead cells
were excluded on the basis of forward and side light
scatter. Data were analyzed with FlowJo (Tree Star, SanFrancisco, CA, USA) and CellQuest software (Becton
Dickinson).
Antibody response
Anti-FMDV antibodies (Ab) were detected by ELISA as
described (Novella et al., 1993). Briefly, 96 well polyvinyl-
chloride (PVC) microplates (Flow Laboratories) were
coated at 4 8C overnight with purified FMDV C-S8c1
(100 ng of VP1). Mouse serum was diluted into PBS/3%
ovalbumin and analyzed for the presence of IgG antibodies
using horseradish peroxidase-conjugated Ig antibodies
(BioRad) to develop the reaction. O-Phenylenediamine-
H2O2 (Sigma) was used as a peroxidase substrate and the
absorbance was read at 490 nm in a Microplate Reader
(Labsystems Multiskan MS). Titers are reported as the
reciprocal of the highest dilution to give an ODA490 of
N0.200. Uninfected control mouse sera were uniformly
negative at the lowest dilution tested, 1:10.
Mice immunizations
Groups of 18 C57BL/6 mice were immunized by two
consecutive ip injections of either gradient-purified binary
ethylenimine (BEI)-inactivated FMDV C-S8c1 preparation
(Bahnemann, 1975) or phosphate-buffered saline (PBS)
(controls) emulsified in Freund’s incomplete adjuvant,
administered 2 weeks apart. Mice were sc inoculated in
the footpad with 104 PFUs of FMDV C-S8c1 (lethal
dose) 2 weeks after the last immunization. Mice were bled
before each immunization and virus challenge. Sera were
tested for FMDV antibodies by ELISA as described
above.
Statistical analyses
Data handling, analysis and graphic representation was
performed using Prism 2.01 (GraphPad Software, San
Diego, CA). Statistical differences were determined using
a Student’s t test (P b 0.05).Acknowledgments
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